Bifidobacterium Cancer Research Results

Bif, Bifidobacterium: Click to Expand ⟱
Features: Bacteria
Bifidobacterium has been associated with improved responses to immune checkpoint inhibitors such as anti–PD-L1 antibodies. The suggested mechanisms include:
-Enhancing dendritic cell function.
-Promoting the activation and proliferation of T cells.
-Modulating cytokine profiles in a way that favors anti-tumor immunity.

Bifidobacterium is a genus of gram-positive, nonmotile, often branched anaerobic bacteria. They are ubiquitous inhabitants of the gastrointestinal tract.

Bifidobacterium longum: Gram-positive, catalase-negative, rod-shaped bacterium.

Here are several notable species:
Bifidobacterium longum
Often found in the human gastrointestinal tract, B. longum has been extensively studied for its role in modulating the immune system and improving gut barrier function. Bifidobacterium breve
Known for its anti-inflammatory properties, B. breve is used in many probiotic formulations and has been researched for its potential to alleviate gastrointestinal disorders, which may indirectly support cancer patients.
Bifidobacterium bifidum
This species is a common member of the gut microbiota and plays a role in maintaining mucosal integrity and immune modulation.
Bifidobacterium infantis
Commonly found in the intestines of breast-fed infants, B. infantis is studied for its beneficial effects on gut health and its potential to modulate immune responses.
Bifidobacterium animalis (including subspecies such as B. animalis subsp. lactis).

Widely incorporated into commercial probiotic products, this species has been researched for its role in digestive health, and emerging studies suggest potential benefits in the context of systemic health, including immune regulation.

Bifidobacterium — a genus of anaerobic, Gram-positive commensal bacteria commonly used as probiotics and studied as a microbiome-based immunomodulatory adjunct rather than a conventional cytotoxic anticancer drug. It is formally classified as a live biotherapeutic / probiotic microbial modality. Standard abbreviations are strain-specific rather than genus-wide, for example B. breve, B. bifidum, and B. longum. Its origin is the human and animal gastrointestinal microbiota, with some strains developed as probiotic formulations. In cancer research, its relevance is mainly strain-dependent and centers on gut–immune–tumor crosstalk, especially dendritic-cell activation, IL-12 signaling, CD8 T-cell priming, and possible enhancement of immune-checkpoint efficacy.

Primary mechanisms (ranked):

  1. Augmentation of dendritic-cell activation and antigen-presentation programs, including IL-12-linked antitumor immune priming.
  2. Promotion of CD8 T-cell expansion, tumor infiltration, and IFN-γ-dominant antitumor immunity.
  3. Sensitization or synergy with PD-1 or PD-L1 checkpoint blockade in preclinical models; probable microbiome biomarker role in some human immunotherapy settings.
  4. Gut barrier and mucosal immune modulation, including epithelial chemokine signaling that favors immune-cell recruitment.
  5. Secondary indirect suppression of tumor growth and increased tumor-cell apoptosis through immune-mediated rather than direct high-exposure cytotoxic mechanisms.

Bioavailability / PK relevance: Classical small-molecule PK metrics are not applicable. Activity depends on viable strain delivery, gastrointestinal survival, colonization or transient persistence, and host microbiome context. The dominant exposure compartment is intestinal; systemic anticancer effects are indirect and immune-mediated.

In-vitro vs systemic exposure relevance: This is not primarily a concentration-driven small-molecule modality. Many reported anticancer effects arise from host–microbe and gut–immune interactions in vivo, so direct in-vitro tumor-cell exposure data have limited translational meaning unless a defined metabolite or engineered strain is being studied.

Clinical evidence status: Strongest evidence for cancer relevance remains preclinical and associative. Human oncology data currently support biomarker and adjunctive-supportive roles more than established tumor-control efficacy. Randomized probiotic trials in cancer patients have mainly evaluated gastrointestinal or perioperative outcomes, with mixed but generally supportive safety and symptom data; direct RCT proof of genus-specific antitumor benefit is not established.

Mechanistic profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Dendritic-cell activation and IL-12 axis ↓ tumor support via improved antigen presentation ↑ DC activation, ↑ IL-12 G Immune priming Most central evidence is immune-mediated, not direct tumor toxicity. Strain effects are heterogeneous; B. breve data are especially notable.
2 CD8 T-cell priming and IFN-γ antitumor immunity ↓ tumor growth, ↑ apoptosis ↑ tumor-specific T-cell activation G Adaptive antitumor response Improved T-cell priming appears downstream of dendritic-cell conditioning and is a major explanation for tumor-control effects.
3 Checkpoint inhibitor sensitization ↑ sensitivity to PD-1 or PD-L1 therapy (context-dependent) ↑ immunotherapy responsiveness G Combination leverage Best supported in mouse models and human microbiome-association studies; not yet validated as a stand-alone clinical antitumor intervention.
4 Gut epithelial chemokine and barrier signaling Indirect ↓ pro-tumor inflammatory or dysbiotic signaling ↑ mucosal integrity, ↑ CCL20-mediated immune-cell recruitment R/G Host interface conditioning Gut-location effects likely precede systemic antitumor immune effects; microbiome context is a major determinant.
5 Direct tumor proliferation suppression and apoptosis ↓ TumCG, ↑ apoptosis ↔ or indirect benefit G Secondary downstream tumor control This is best interpreted as immune-mediated downstream biology rather than evidence of direct genus-wide tumor-cell cytotoxicity.
6 Clinical Translation Constraint ↔ strain-dependent ↔ host-dependent G Deployment limitation Translation is constrained by strain specificity, product quality control, colonization variability, antibiotic exposure, concurrent therapy effects, and infection risk in severely immunocompromised hosts.

P: 0–30 min

R: 30 min–3 hr

G: >3 hr
Scientific Papers found: Click to Expand⟱
1250- Bif,    Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12
- in-vitro, SCC, NA
TumCG↓, Apoptosis↑, CCL20↑, IL12↑,
5621- Bif,  immuno,    Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
TumCG↓, GutMicro↑,
5622- Bif,    Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice
- in-vivo, Var, NA
eff↑, Imm↑, IFN-γ↑,
5623- Bif,    Bifidobacterium breve predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients
- Study, NSCLC, NA
GutMicro↑, OS↑, eff↑,
5625- Bif,  immuno,    The gut microbiome and cancer response to immune checkpoint inhibitors
- Review, Var, NA
eff↑, eff↓,
5626- Bif,    Bifidobacterium in anticancer immunochemotherapy: friend or foe?
- Review, Var, NA
*Inflam↓, *Treg lymp↑, *IL10?, Imm↑, eff↑,
5627- Bif,    Efficacy and Safety of Probiotics as Adjunctive Therapy in Cancer Treatment: A Comprehensive Systematic Review and Meta-Analysis
- Review, Var, NA
Diar↓,
5628- Bif,  immuno,    Bifidobacterium modulation of tumor immunotherapy and its mechanism
- Review, Var, NA
Imm↑, Risk↓, GutMicro↑, AntiTum↑, OS↑, selectivity↑, eff↑,
5629- Bif,  ProBio,    Gut microbiota shapes cancer immunotherapy responses
- Review, Var, NA
eff↑, DCells↑, CD8+↑, eff↑, AntiTum↑, other↑, selectivity↑, GutMicro↑,
5624- ProBio,  Bif,    A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer
- Trial, Testi, NA
Dose↝, TNF-α↓, IL6↓, IL10↓, IL12↓, IL22↓, toxicity↓,
5630- ProBio,  Bif,    EFFICACY OF PROBIOTICS IN PREVENTING CHEMOTHERAPY-INDUCED DIARRHEA IN GASTROINTESTINAL CANCER PATIENTS
- Trial, GC, NA
Dose↝, Diar⇅,

Showing Research Papers: 1 to 11 of 11

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 11

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

Diar↓, 1,   Diar⇅, 1,  

Cell Death ⓘ

Apoptosis↑, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 2,  

Immune & Inflammatory Signaling ⓘ

CCL20↑, 1,   DCells↑, 1,   IFN-γ↑, 1,   IL10↓, 1,   IL12↓, 1,   IL12↑, 1,   IL22↓, 1,   IL6↓, 1,   Imm↑, 3,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 2,   eff↓, 1,   eff↑, 7,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

GutMicro↑, 4,   IL6↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 2,   OS↑, 2,   Risk↓, 1,   toxicity↓, 1,  

Infection & Microbiome ⓘ

CD8+↑, 1,  
Total Targets: 26

Pathway results for Effect on Normal Cells:


Migration ⓘ

Treg lymp↑, 1,  

Immune & Inflammatory Signaling ⓘ

IL10?, 1,   Inflam↓, 1,  
Total Targets: 3

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:44  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page